Events and Announcements


Please save the date - the Annual Sarcoma Conference in 2017 will be held on October 13th and 14th at Flinders University in Adelaide.

The theme for this years conference is AYA Sarcomas: Current Scenario and the Way Forward

Click here for more information.


ASSG is now on Facebook and Twitter

        

ASSG is now on Facebook and Twitter! Like us on Facebook and follow us on Twitter to help us raise awareness of sarcoma and grow our community.


The Annual 2016 Sarcoma Conference

October 15 & 16, 2016

The 2016 Annual Sarcoma Meeting, which the Australian Sarcoma Group and Australasian Sarcoma Study Group jointly convene, was held in Sydney, Australia October 15th and 16th at the Garvan Institute of Medical Research.  The theme was “Translation: from Biology to Patient Care.” We were delighted to host three high profile international speakers:

Dr Matt van de RijnProfessor, Department of Pathology, Stanford University Medical Center, USA. Professor van de Rijn’s group identified the genetic rearrangement within Tenosynovial Giant Cell Tumors, which has led to the development of effective systemic therapies for this disease (Tap et al., New England Journal of Medicine, 2015).

Dr Miguel Ayerza - Surgical oncologist Italian Hospital of Buenos Aires Argentina. Professor Miguel Ayerza is a Professor of Orthopaedic Surgery at the University of Buenos Aires and is a renowned orthopaedic oncologist who has served on the committees of several the International societies and as President of the Association of Bone and Joint Surgeons.

Dr Lee Helman - Head of Molecular Oncology and Acting Director, Centre for Cancer Research, National Cancer Institute, USA. Dr. Helman's laboratory focuses on rhabdomyosarcoma, Ewing's sarcoma, osteosarcoma, and pediatric gastrointestinal stromal tumours.  His group aims to: (1) determine the pathophysiologic consequences of IGF signaling; (2) identify the molecular/biochemical determinants of the biology of these sarcomas; and (3) apply preclinical laboratory findings to develop novel clinical studies for these sarcomas.

 

International Clinical Trials Day

May 20 marked International Clinical Trials Day, held annually to recognise the world’s first clinical trial which took place in 1747.

To mark 2016 International Clinical Trials Day today, the Cancer Cooperative Trials Groups (CCTG) of Australia have, for the first time, come together to release a Fact Sheet providing information for people interested in taking part in a clinical trial.

The information resource is the result of close collaboration and consultation between a group of consumers, together with 14 cancer trials groups based in Australia and New Zealand and aims to encourage participation in clinical trials.

To see the full media release please click here.

New clinical trial opening at the Royal Prince Alfred Hospital and Chris O'Brien Lifehouse

NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating and Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall

RATIONALE: Radiation therapy given before surgery of soft tissue sarcoma decreases the size of the tumor mass and the presence of malignant cells in its peripheral region. NBTXR3 and radiation therapy may kill more cancer cells and increase the tumor shrinkage rendering surgery more feasible or easier and achieve better local control of the tumor.

PURPOSE: This phase II/III is a prospective randomized, multi-center, open-label and active controlled two arms study in patients with locally advanced soft tissue sarcoma (STS) of the extremity and trunk wall. Patients will be randomized to receive either NBTXR3 as intratumor injection, activated by external beam radiation therapy or external beam radiation therapy alone, as preoperative treatment. Once the radiotherapy treatment is completed, tumor surgery will be performed in all patients.

For more information please click here or visit the our research studies page for more clinical trials.

 

ACORD Workshop opportunity

September 11-17, 2016

The ASSG has agreed to sponsor a clinician researcher to attend the ACORD Protocol Development Workshop (a 7 day residential educational program in effective clinical trial design and development). The ACORD 2016 workshop will be  held September 11-17, at Magenta Shores, Tuggerah, New South Wales, Australia.This is a wonderful opportunity and the ASSG hopes that you will consider applying.

The Australasian Sarcoma Study Group clinician must submit their application online by the 26th of Feb 2016 at http://acord.org.au/applicantinformation.asp

Once the selection process has taken place ACORD will get in touch with the nominated clinician, confirm their place, confirm they are supported by the ASSG and are not required to pay the registration fee or any other workshop expenses.

 

Cancer Australia’s Priority-driven Collaborative Cancer Research Scheme 2016
February, 2016

Cancer Australia’s Priority-driven Collaborative Cancer Research Scheme is an annual national research project grants scheme which funds cancer research in identified priority areas to help reduce the impact of cancer in the community and improve outcomes for people affected by cancer. In 2016, Cancer Australia and its partners:

  • Australasian Sarcoma Study Group

  • Cancer Council Australia

  • Cancer Council NSW

  • Cure Cancer Australia

  • National Breast Cancer Foundation

  • The Kids’ Cancer Project

will offer funding for project grants in identified priority areas. Please click here for more information.

 

The Annual 2015 Sarcoma Conference

Brisbane October 17 & 18 2015

2015 returned the ASSG and the ASG (Australian Sarcoma Group) back to our usual format with the Annual Sarcoma Conference held over two days at the Translational Research Institute hosted by local sarcoma experts.  In Brisbane, Dr Scott Sommerville, Dr Warren Joubert and Dr David Pryor, along with the organizing committee, put together an interesting and multidisciplinary scientific programme under the theme “Precision Treatment in Sarcoma Care.” 

We were delighted to have three international sarcoma experts speaking at the conference. Dr William Tap, Medical Oncologist from Memorial Sloane Kettering Medical Center NY Dr David Kirsch, Radiation Oncologist from Duke University Chapel Hill North Carolina Dr Shekhar Kumta, Surgical Oncologist from The Chinese University of Hong Kong


                 

 




Last update: 07-Apr-2017 09:11 AM




 

 

 

 

 

 

 

 

 

 Find a Sarcoma Specialist
 Ask a Question
Support Sarcoma Research